Table D-21. Evidence table for studies addressing management of PPH (Kim 2013b)

| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| Author:Kim et al., 201326Country:KoreaEnrollment period: March 2004 – January 2011Birth setting: hospitalFacility characteristics: Tertiary care Funding: NRDesign: Retrospective case series | **Intervention:** Pelvic arterial embolization (PAE)**Groups:****G1a:** successful PAE (intervention)**G1b:** failed PAE (intervention)N at enrollment: **G1:** 257**G1a:** 233**G1b:** 24Duration of treatment: NRTiming of treatment: NROrder of treatment:PAE was performed due to continued bleeding despite appropriate medical and/or surgical treatmentsLength of follow-up: NR | **Operational definition of PPH:** NR**Definition of success of treatment:** Technical success was defined as the cessation of bleeding on angiography and/or angiographically successful emboli- zation of the uterine or anterior division of the hypogastric artery (12). Clinical success was defined as the cessation of bleeding after one PAE session. Clinical failure was defined as the need for subsequent intervention, including repeat embolization or additional surgery during the hospital stay.**Method of blood loss measurement:** NR**Severity:** NRInclusion criteria: * Patients undergoing PAE at hospital within study period

Exclusion criteria: NR**Maternal age, yrs, median (range):****G1:** 32 (20-40)**Maternal age >32 y, n (%):****G1a:** 102 (87.2)**G1b**: 15 (12.8)p = 0.08**Primiparity, n:** **G1a:** 150 (92.6)**G1b:** 12 (7.4) p = 0.19**Weeks gestation:** NR**Single pregnancy:** NR**Multiple pregnancy:** NR**Race/ethnicity:** NR**BMI:** NR**Baseline hemoglobin (<8 g/dl):** **G1a:** 103 (85.1)**G1b:** 18 (14.9)p < 0.01**SES:** NR**Mode of birth, n:** Cesarean, n (%):**G1a:** 103 (92.0)**G1b**: 9 (8.0)**Risk factors, n (%):** PAE after failed surgical procedure, n (%): 9**G1a:** 7**G1b:** 2p = .20**Primary etiology of PPH, n (%):** Atony: 154**G1a:** 140 (89.7)**G1b:** 16 (10.3)p = 0.53Lower genital tract laceration: 44**G1a:** 38 (86.4)**G1b:** 6 (13.6)p = 0.39Placenta accrete: 22**G1a:** 20 (90.9)**G1b:** 2 (9.1)p = 0.66Retained placental fragments: 19**G1a:** 19 (100)**G1b:** 0Placenta previa: 16**G1a:** 16**G1b:** 0 | **Harms pre-specified:** Yes**Harms, n (%):**Total **G1a:** 22 (9.4)**G1b:** 9 (37.5)p < 0.01**Embolization related total:****G1a:** 11**G1b:** 4p = 0.01**Paresthesia:** 10**G1a:** 7**G1b:** 3**Uterine abscess**: 3**G1a:** 2**G1b:** 1**Postembolization syndrome:** 2**G1a:** 2**G1b:** 0**Transfusion related:** Pulmonary edema: 5**G1a:** 4**G1b:** 1p = 0.41**Hypovolemia-related total:** 11**G1a:** 7**G1b:** 4p <0.01**Cerebral infarction:** 5**G1a:** 2**G1b:** 3**Optic nerve ischemia:** 2**G1a:** 2**G1b:** 0**Acute renal failure:** 2**G1a:** 2**G1b:** 0**Multiorgan failure:****G1a:** 1**G1b:** 1 |